Cello is a global healthcare-focused advisory firm comprised of a set of leading scientific, commercial advisory and digital delivery capabilities. Cello currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.
Arsenal Capital Partners is a US based private equity firm with a strong track record in building market-leading companies in the life sciences market.
The acquisition was effected by means of a scheme of arrangement under the Companies Act 2006 which became effective on 11 August 2020, Cello shareholders received 161 pence in cash for each Cello share held. The acquisition valued Cello at approximately £178.8 million.
For further details on the transaction, please see https://cellohealth.com/news/arsenal-capital-partners-completes-182-million-acquisition-of-cello-health/